Blair William & Co. IL increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 106.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 313,542 shares of the company's stock after acquiring an additional 161,530 shares during the period. Blair William & Co. IL's holdings in ImmunityBio were worth $1,684,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Meridian Management Co. bought a new position in shares of ImmunityBio in the 4th quarter worth $46,000. Tower Research Capital LLC TRC increased its holdings in shares of ImmunityBio by 43.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company's stock worth $47,000 after buying an additional 2,844 shares during the last quarter. Private Advisor Group LLC bought a new position in shares of ImmunityBio in the 4th quarter worth $53,000. Simplicity Wealth LLC bought a new position in shares of ImmunityBio in the 1st quarter worth $58,000. Finally, Bleakley Financial Group LLC purchased a new stake in shares of ImmunityBio in the 1st quarter valued at $58,000. Institutional investors own 8.58% of the company's stock.
Analysts Set New Price Targets
Separately, Piper Sandler upped their price objective on shares of ImmunityBio from $5.00 to $6.00 and gave the company a "neutral" rating in a research note on Monday, April 29th.
View Our Latest Stock Report on IBRX
ImmunityBio Stock Down 1.4 %
Shares of ImmunityBio stock traded down $0.08 during trading on Monday, reaching $5.71. The company's stock had a trading volume of 2,509,338 shares, compared to its average volume of 5,198,005. ImmunityBio, Inc. has a 52-week low of $1.25 and a 52-week high of $10.53. The company has a market cap of $3.95 billion, a price-to-earnings ratio of -5.24 and a beta of 1.07. The firm's 50-day moving average is $6.52 and its two-hundred day moving average is $5.66.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.03 million. On average, equities research analysts anticipate that ImmunityBio, Inc. will post -0.75 EPS for the current year.
ImmunityBio Profile
(
Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
